Search for: "Grant v. Pfizer Inc." Results 21 - 40 of 349
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Sep 2021, 2:10 am by Rose Hughes
The US Courts of Appeal of the Federal Circuit (CAFC) found in Belcher Pharmaceuticals v Hospira, Inc that a formulation patent was unenforceable in view of inequitable conduct, in the form of contradictory submissions to the patent office and the regulatory agency (FDA) by the patentee. [read post]
13 Jul 2021, 10:58 am by Simon Lester
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]
9 Jan 2021, 9:16 am by Gregory B. Williams
January 7, 2021), the Court granted in part the motion of Defendants Hospira, Inc. and Pfizer, Inc. to stay Civil Action No. 20-0561 until 14 days after resolution of Amgen Inc. et al. v. [read post]
16 Mar 2020, 9:12 am by Lawrence B. Ebert
Pfizer, 558 F.3d 284, 292 (4th Cir. 2009). [read post]
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 48. [12] See Free World Trust, supra, at paragraph 13; Apotex Inc v Wellcome Foundation Ltd, 2002 SCC 77 at paragraph 37, [2002] 4 SCR 153; AstraZeneca Canada Inc v Apotex Inc, 2017 SCC 36 at paragraph 39, [2017] 1 SCR 943 [13] See Free World Trust, supra, at paragraphs 33–43; applied in Seedlings Life Science Ventures, LLC v. [read post]
23 Jan 2020, 10:37 pm by Schachtman
Last week, Judge Seeborg ruled by granting in part, and denying in part, the parties’ motions.[8] The Decision The MDL trial judge’s opinion is noteworthy in many respects. [read post]
23 Jan 2020, 4:00 am by Alan Macek
” Arkipelago Architecture Inc. v. [read post]
24 Jul 2019, 6:22 am by Philipp Widera
Legal background regarding Arrow-declarations The underlying jurisdiction was established in Arrow Generics v Merck & Co Inc [2007] FSR 39 and approved by the Court of Appeal in Fujifilm v AbbVie [2017] EWCA Civ. 1. [read post]